New draft quality standard aims to boost early intervention and consistent care for adults living with long-term health conditions.

A new analysis from the landmark SUMMIT trial has revealed that tirzepatide, a drug already approved for weight loss and type 2 diabetes, offers significant benefits for people living with obesity, chronic kidney disease (CKD), and heart failure with preserved ejection fraction (HFpEF).

The number of teenagers in England who are living with overweight or obese has risen by 50 per cent since 2008, according to new research. Experts say the sharp increase is largely driven by the consumption of ultra-processed foods and increasingly sedentary lifestyles shaped by excessive screen time.

A new international analysis has revealed important insights into the two-way relationship between obesity and obstructive sleep apnea (OSA), reinforcing the need for a broader approach to identifying and managing the condition.

A new phase 2 trial has shown that higher doses of semaglutide — up to 16 mg weekly — may deliver greater weight loss benefits in people with living with type 2 diabetes and overweight or obesity, though with increased side effects.

Novo Nordisk has submitted a pill version of its obesity drug for approval by the US Food and Drug Administration, the company has confirmed.

All schools in Spain are now legally required to serve fruit and vegetables daily and include fish in lunches at least once a week, under new legislation designed to combat childhood obesity.

New UK research being presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) reveals that women are significantly more aware of obesity medications known as GLP-1/GIP receptor agonists than men. These medications include semaglutide and tirzepatide.

A US report has highlighted a worrying increase in obesity-related cancer deaths and warns that more cases may be diagnosed at a later stage due to disruptions caused by the COVID-19 pandemic.

The United States could see one of the sharpest drops in obesity rates globally, thanks to the growing use of weight loss drugs such as Ozempic and Wegovy, according to a new report.

Medications used to treat obesity and type 2 diabetes — particularly semaglutides such as Ozempic and Wegovy — may reduce the risk of dementia, according to new research.

A new study has turned a long-standing belief about cardiovascular disease on its head. Rather than being caused by a build-up of fat molecules called ceramides, researchers have found that in obesity and diabetes, it’s actually the decrease of these fats in blood vessels that may lead to health problems.

Marriage may bring love and companionship, but it also appears to come with a greater risk of obesity — especially for men. A new study suggests that men who are married are 3.2 times more likely to become obese compared to their unmarried counterparts.

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) has revealed that a new diagnosis of type 2 diabetes is associated with an increased risk of developing certain obesity-related cancers. However, the study found that this link does not apply to all obesity-related cancers.

New research published in Nature reveals that chronic exposure to high-fat diets diminishes the brain's reward response to food, reducing the pleasure associated with eating.

The NHS has released interim commissioning guidance to support the implementation of the NICE Technology Appraisal (NICE TA1026) and the NICE Funding Variation for tirzepatide (Mounjaro®) in the management of obesity.

New research set to be presented at the European Congress on Obesity (ECO 2025) in Malaga, Spain (11-14 May) reveals that children who are living with overweight or obesity face a significantly higher risk of developing chronic obstructive pulmonary disease (COPD) in adulthood.

Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with Wegovy® (semaglutide injection) 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults living with overweight or obesity and established cardiovascular disease (CVD).

Novo Nordisk today presented full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (semaglutide tablets, 14mg) significantly reduced the risk of major adverse cardiovascular events in adults living with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

Novo Nordisk has secured global rights to China-based United Laboratories International's experimental weight-loss drug, UBT251, in a deal worth up to $2 billion.